Maze Therapeutics adds Paula Johnson and Sophie Kornowski to board

Maze Therapeutics, Inc. announced on August 13, 2026 that its Board of Directors appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, both effective that date.¹ Dr. Johnson's term runs through the 2028 annual meeting, while Dr. Kornowski's term runs through the 2029 annual meeting.¹

Dr. Johnson, age 66, has been President of Wellesley College since 2016 and previously founded the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital, where she also served as Chief of the Division of Women's Health from 2002 to 2016, alongside faculty roles at Harvard Medical School and the Harvard T.H. Chan School of Public Health.¹ She has served on the Johnson & Johnson board since 2023.¹

Dr. Kornowski, age 63, served as CEO of Boston Pharmaceuticals from 2022 to 2025, was a Senior Partner at Gurnet Point Capital from 2018 to 2025, and earlier held senior partnering and executive roles at F. Hoffmann-La Roche AG and Chugai Pharmaceutical.¹

Johnson was named to the nominating and corporate governance committee, while Kornowski joins the audit and compensation committees.¹ Both directors will receive standard non-employee compensation, including a pro-rated portion of the $40,000 annual cash retainer and an option to purchase 36,000 shares vesting monthly over three years.¹

The filing also disclosed board reclassification: Nancy C. Andrews shifted from a Class III to Class II director, and Hervé Hoppenot shifted from Class II to Class III, to keep the board divided into roughly equal classes.¹

Separately, CEO Jason Coloma noted upcoming pipeline milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027, and initial data from MZE782 in 2027.¹